Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic ...
Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).
The update removes the requirement for Leqvio to be used as an adjunct to statin therapy. The Food and Drug Administration (FDA) has approved a labeling update for Leqvio ® (inclisiran) allowing for ...
Inclisiran (Leqvio) may now be used as a first-line treatment option for patients with high cholesterol levels, according to an announcement from drugmaker Novartis. The US Food and Drug ...
Leqvio is a brand-name prescription medication containing the active ingredient inclisiran. A healthcare professional administers it as an injection under the skin. Original Medicare Part B covers ...
LISBON, Portugal — Using RNA interference to inhibit proprotein convertase subtilisin kexin type 9 (PCSK9) synthesis lowers levels of atherogenic lipoproteins across the board, new results suggest. At ...
The GIP/GLP-1 dual agonist tirzepatide (Mounjaro) showed cardiovascular protective benefits over dulaglutide (Trulicity) in the phase III SURPASS-CVOT trial of diabetes patients with heart disease, ...
More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...
(RTTNews) - Novartis announced Thursday said that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran), enabling its use as monotherapy along with diet and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results